Fredrick B. Hagemeister, M.D.

Peer-Reviewed Articles

1. Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer 130(6):876-885, 2024. e-Pub 2023. PMID: 37985359.
2. Xu-Monette ZY, Li Y, Snyder T, Yu T, Lu T, Tzankov A, Visco C, Bhagat G, Qian W, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Wang Y, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Fan X, van Krieken JH, Piris MA, Winter JN, Au Q, Kirsch I, Zhang M, Shaughnessy J, Xu B, Young KH. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clin Cancer Res 29(23):4808-4821, 2023. PMID: 37728879.
3. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. PMID: 37586321.
4. Li Y, Xu-Monette ZY, Abramson J, Sohani AR, Bhagat G, Tzankov A, Visco C, Zhang S, Dybkaer K, Pan Z, Xu M, Tam W, Zu Y, Hsi ED, Hagemeister FB, Go H, van Krieken JH, Winter JN, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Wang Y, Zhang M, Young KH. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv 7(7):1308-1311, 2023. e-Pub 2022. PMID: 36399513.
5. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
6. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2022. PMID: 36068929.
7. Cherng HJ, Alig S, Oki Y, Nastoupil LJ, Fayad LE, Neelapu SS, Turturro F, Hagemeister FB, Craig A, Macaulay C, Rodriguez MA, Lee HJJ, McDonnell T, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. e-Pub 2022. PMID: 36375046.
8. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov 3(5):428-443, 2022. e-Pub 2022. PMID: 35687817.
9. Khan M, Hagemeister F, Wang M, Ahmed S. A review of pathobiology and therapies for classic Hodgkin lymphoma. Blood Rev 55:100949, 2022. e-Pub 2022. PMID: 35396126.
10. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
11. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol:JCO2200597. e-Pub 2022. PMID: 35952327.
12. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. PMID: 35359004.
13. Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns H, Nagy M, Tzankov A, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Sun X, Han X, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Albitar M, You H, Young KH. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res 28(5):972-983, 2022. e-Pub 2022. PMID: 34980601.
14. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
15. Albitar M, Zhang H, Goy A, Xu-Monette ZY, Bhagat G, Visco C, Tzankov A, Fang X, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Young KH. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J 12(2):25, 2022. e-Pub 2022. PMID: 35105854.
16. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):1-10, 2022. e-Pub 2021. PMID: 34435552.
17. Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol 40(2):202-212, 2022. e-Pub 2021. PMID: 34797699.
18. Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma 62(14):1-11, 2021. e-Pub 2021. PMID: 34365878.
19. Khan M, Samaniego F, Hagemeister FB, Iyer SP. Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions. Cancers (Basel) 13(22), 2021. e-Pub 2021. PMID: 34830782.
20. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
21. Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM, Zhu F, Fang X, Deng M, Zhang M, Hagemeister FB, Li Y, Orlowski RZ, Lee HC, Young KH. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Neoplasia 23(4):361-374, 2021. e-Pub 2021. PMID: 33735664.
22. Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Hagemeister F, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Liu P, Young KH. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res 19(2):249-260, 2021. e-Pub 2020. PMID: 33154093.
23. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood 137(8):1124-1129, 2021. PMID: 32932518.
24. Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplant 56(1):278-281, 2021. e-Pub 2020. PMID: 32636464.
25. Samaniego F, McLaughlin P, Neelapu SS, Feng L, Fanale M, Nastoupil L, Rodriguez MA, Pro B, Taylor E, Hagemeister FB, Fowler N. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma 62(1):1-10, 2021. e-Pub 2020. PMID: 32924687.
26. You H, Xu-Monette ZY, Wei L, Nunns H, Nagy ML, Bhagat G, Fang X, Zhu F, Visco C, Tzankov A, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Van Krieken JH, Piris MA, Winter JN, Li Y, Au Q, Xu B, Albitar M, Young KH. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology 10(1):1928365, 2021. e-Pub 2021. PMID: 34350060.
27. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma 61(12):2985-2989, 2020. e-Pub 2020. PMID: 32628087.
28. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
29. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res 26(21):5579-5587, 2020. e-Pub 2020. PMID: 33055173.
30. Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol 13(1):148, 2020. e-Pub 2020. PMID: 33148342.
31. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. PMID: 32822484.
32. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(7):1907-1913, 2020. e-Pub 2019. PMID: 31601688.
33. Xu-Monette ZY, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister FB, Shahbaba B, De Dios I, Zhang H, Li Y, Xu B, Albitar M, Young KH. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv 4(14):3391-3404, 2020. PMID: 32722783.
34. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
35. Zhou H, Xu-Monette ZY, Xiao L, Strati P, Hagemeister FB, He Y, Chen H, Li Y, Manyam GC, Li Y, Montes-Moreno S, Piris MA, Young KH. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J 10(5):49, 2020. e-Pub 2020. PMID: 32366834.
36. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61(2):1-9, 2020. e-Pub 2019. PMID: 31533521.
37. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 105(1):e26-e28, 2020. e-Pub 2019. PMID: 31073068.
38. Sathyanarayanan V, Issa A, Pinto R, Fayad LE, Loghavi S, Hagemeister F, Westin JR. Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience. Clin Lymphoma Myeloma Leuk 19(11):709-714, 2019. e-Pub 2019. PMID: 31446000.
39. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
40. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. e-Pub 2019. PMID: 30919940.
41. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol. e-Pub 2019. PMID: 30785215.
42. Styskel BA, Lopez-Mattei J, Jimenez CA, Stewart J, Hagemeister FB, Faiz SA. Ibrutinib-Associated Serositis in Mantle Cell Lymphoma. Am J Respir Crit Care Med. e-Pub 2019. PMID: 30802411.
43. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol. e-Pub 2019. PMID: 30820940.
44. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol 3(4):639-646, 2018. e-Pub 2018. PMID: 30370365.
45. Sagiv O, Thakar SD, Manning JT, Kandl TJ, Fayad LE, Fowler N, Hagemeister FB, Fanale MA, Pinnix CC, Samaniego F, Esmaeli B. Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. Ophthalmic Plast Reconstr Surg. e-Pub 2018. PMID: 30124609.
46. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys 101(3):530-540, 2018. e-Pub 2018. PMID: 29681481.
47. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 40(6):1335, 2018. e-Pub 2018. PMID: 29851218.
48. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer 124(12):2561-2569, 2018. e-Pub 2018. PMID: 29723393.
49. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. e-Pub 2018. PMID: 29785709.
50. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28792260.
51. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
52. Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, Akhtari M, Allen PK, Atkinson BJ, Smith GL, Pinnix CC, Milgrom SA, Abou Yehia Z, Osborne EM, Oki Y, Lee H, Hagemeister F, Fanale MA. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol 180(4):545-549, 2018. e-Pub 2017. PMID: 29271057.
53. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2017. PMID: 29196178.
54. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
55. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol 179(5):851-854, 2017. e-Pub 2016. PMID: 27502933.
56. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). Leuk Lymphoma 58(12):1-12, 2017. e-Pub 2017. PMID: 28482717.
57. Nair R, Tabchi S, Hagemeister F. Obinutuzumab Treatment of Follicular Lymphoma. N Engl J Med 377(26):2605, 2017. PMID: 29281573.
58. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 179(3):503-506, 2017. e-Pub 2016. PMID: 27378601.
59. Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?. Br J Haematol 179(3):488-496, 2017. e-Pub 2017. PMID: 28832956.
60. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthal Plast Reconstr Surg 33(5):355-360, 2017. e-Pub 2016. PMID: 27636243.
61. Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget 8(25):41620-41630, 2017. PMID: 28404929.
62. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
63. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad L, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin J, Wang M, McLaughlin P, Pinnix C, Milgrom S, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. Blood. e-Pub 2017. PMID: 28522441.
64. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
65. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. e-Pub 2017. PMID: 28370694.
66. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. e-Pub 2016. PMID: 27983760.
67. Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, de Winde CM, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, van Krieken JH, Medeiros LJ, Li Y, van Spriel AB, Young KH. Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. e-Pub 2016. PMID: 27760757.
68. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 2016. e-Pub 2016. PMID: 27227654.
69. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, fludarabine and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 22(7):1333-7, 2016. e-Pub 2016. PMID: 27064056.
70. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 2016. e-Pub 2016. PMID: 27091808.
71. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. e-Pub 2016. PMID: 27448187.
72. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. e-Pub 2016. PMID: 27351173.
73. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 2016. e-Pub 2016. PMID: 26802151.
74. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 2016. e-Pub 2015. PMID: 26795083.
75. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 2016. e-Pub 2015. PMID: 26648336.
76. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48-56, 2016. e-Pub 2015. PMID: 26640039.
77. Sathyanarayanan V, Hagemeister F. Targeted therapies for Hodgkin lymphoma: results of recent trials. Rinsho Ketsueki 57(10):2049-2053, 2016. PMID: 27795513.
78. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 2015. e-Pub 2015. PMID: 26358140.
79. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. e-Pub 2015. PMID: 26683805.
80. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant 21(11):1914-20, 2015. e-Pub 2015. PMID: 26071868.
81. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica 100(11):e454-7, 2015. e-Pub 2015. PMID: 26250576.
82. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
83. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 100(7):e272-4, 2015. e-Pub 2015. PMID: 25820332.
84. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 26(6):1175-9, 2015. e-Pub 2015. PMID: 25712454.
85. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 2015. e-Pub 2015. PMID: 25828695.
86. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by (18)fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 2015. PMID: 25863759.
87. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for hodgkin and non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-82, 2015. PMID: 25863764.
88. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2014. PMID: 25445468.
89. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
90. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 2014. e-Pub 2014. PMID: 25039868.
91. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double Hit Lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
92. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. Int J Radiat Oncol Biol Phys 89(2):384-91, 2014. e-Pub 2014. PMID: 24721592.
93. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
94. Thompson MA, Westin JR, Hagemeister FB. Bone mineral density screening should be routine in lymphoma patients. Ann Oncol 25(4):913-4, 2014. PMID: 24667725.
95. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma 54(12):2631-8, 2013. e-Pub 2013. PMID: 23488661.
96. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
97. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19(24):6882-90, 2013. e-Pub 2013. PMID: 24097867.
98. Westin J, Hagemeister F. R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care?. J Comp Eff Res 2(6):537-40, 2013. PMID: 24236792.
99. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 2013. e-Pub 2013. PMID: 23545991.
100. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol 162(5):631-8, 2013. e-Pub 2013. PMID: 23802738.
101. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 162(1):138-41, 2013. e-Pub 2013. PMID: 23590726.
102. Churpek JE, Pro B, van Besien K, Kline J, Conner K, Wade JL, Hagemeister F, Karrison T, Smith SM. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer 119(9):1683-9, 2013. e-Pub 2013. PMID: 23310949.
103. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 2013. e-Pub 2012. PMID: 23276888.
104. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. Clin Lymphoma Myeloma Leuk 13(1):15-8, 2013. e-Pub 2012. PMID: 23137719.
105. Hagemeister FB. 'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy?. BioDrugs 26(6):363-76, 2012. PMID: 23057946.
106. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. J Clin Oncol 30(33):4161-7, 2012. e-Pub 2012. PMID: 22965964.
107. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. J Clin Oncol 30(22):2776-82, 2012. e-Pub 2012. PMID: 22753910.
108. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 2012. e-Pub 2012. PMID: 22677155.
109. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 2012. e-Pub 2011. PMID: 22015451.
110. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin's lymphoma: A 10-year follow-up study. Leuk Lymphoma 53(5):801-6, 2012. e-Pub 2012. PMID: 22023528.
111. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
112. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 2012. PMID: 22383790.
113. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 53(1):50-6, 2012. e-Pub 2011. PMID: 21895545.
114. Thomas DA, O'Brien S, Faderl S, Mannig Jt Jr, Romaguera JE, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt-like lymphoma: Should these be treated as different diseases?. Curr Hematol Malig Rep 6(1):58-66, 2011. PMID: 21191675.
115. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S.. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 123(10):935-941, 2010. PMID: 20920696.
116. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-208, 2010.
117. Morris GJ, Dotan E, Smith MR, Hagemeister FB Jr, Brereton HD. Gastric mucosa-associated lymphoid tissue lymphoma. Semin Oncol 37(3):183-7, 2010. PMID: 20709202.
118. Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-72, 2010. PMID: 20166765.
119. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 2009. PMID: 19770379.
120. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144-52, 2009. PMID: 19168784.
121. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Rayad L, Wayne SM, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Annals of Oncology 20(4):709-14, 2009. PMID: 19150940.
122. Morschauser F, Dreyling M, Rohatiner A, Hagemeister F and Bischof-Delaloye A. Rationale for consolidation to improve progression-free survival in patinets with non-Hodgkin's lymphoma: a review of the evidence. The Oncologist 14(Suppl 2):17-29, 2009. PMID: 19819921.
123. Overman, MJ; Feng, L; Pro, B; McLaughlin, P; Hess, M; Samaniego, F; Younes, A; Romaguera, JE; Hagemeister, FB; Kwak, L; Cabanillas, F; Rodriguez, MA; Fayad, LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19 (3)(3):553-559, 2008. e-Pub 2007. PMID: 18083690.
124. Anderlini P, Saliba R, Acholonu S, Giralt SA, Anderson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-Melphalan as preparative regimen for reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's Lymphoma: The updated M.D. Anderson Cancer Center experience. Hematological 93 (2):257-64, 2008.
125. Oki, Y., Pro, B., Fayad, L.E., Romaguera, J., Samaniego, F., Hagemeister, F., Neelapu, S., McLaughlin, P., Goy, A., Younes, A.. Phase 2 study of gemcitabine in combination with Rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112 (4):831-836, 2008.
126. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez MA, Romaguera JE, Hagemeister FB, Pro B.. Follicular Dendritic Cell Sarcoma: A Report of 14 Cases and a Review of the Literature. Am J Hematol 82(8)(8):725-28, 2007. PMID: 17373675.
127. Leonard JP, Friedberg JW, Hagemeister FB, Levine AM. Combination treatment of approaches and novel therapies for lymphoma. Clinical Advances of Hematology Oncology 8(12):4-20, 2007.
128. Hagemeister FB, Luis Fayad. The FLIPI and the R-FLIPI: Are we finally ready to use them in clinical trials?. Am J Hematol/Onc 6:364-68, 2007.
129. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2007. PMID: 17233846.
130. Fayad L, Hagemeister FB. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: Newer therapies needed. Leuk Lymphoma 48:657-58, 2007.
131. Hagemeister FB. Hodgkin's Lymphoma in the Elderly: Who is "Older" and is the Disease Really Worse in Older Patients?. Oncology 21:996-1002, 2007.
132. Hagemeister FB. Hodgkin’s lymphoma in younger patients: Lessons learned on the road to success. Oncology (Williston Park) 21:434-40, 2007.
133. Dang NH, Fayad L, McLaughlin P, Romaguera JE, Hagemeister FB, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin’s lymphoma. Br J Haematol 138(4):502-05, 2007.
134. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister FB, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481-89, 2007.
135. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad,, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 2006. e-Pub 2006. PMID: 17054068.
136. Samaniego, F; Fayad, LE; Pro, B; McLaughlin, P; Rodriguez, MA; Hagemeister, FB; Fanale, M; Neelapu, S; Younes, A; Kwak, LW. Pentostatin combined with cyclophosphamide, and rituximab induces high response rates in patients with untreated indolent B-cell lymphoma. Blood 108(11):263B-263B, 2006.
137. Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47(9):1818-21, 2006. PMID: 17064994.
138. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-302, 2006. PMID: 16902984.
139. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481-85, 2006. PMID: 16396772.
140. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera JE, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24(10):1582-89, 2006. PMID: 16575009.
141. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569-80, 2006. PMID: 16502413.
142. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 104(4):781-7, 2005. PMID: 15973667.
143. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104(2):345-53, 2005. PMID: 15948158.
144. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105(12):4573-5, 2005. e-Pub 2005. PMID: 15741224.
145. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-75, 2005. PMID: 15613697.
146. Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 10:150-9, 2005. PMID: 15709217.
147. Hagemeister F, Huen A. The status of allopurinol in the management of tumor lysis syndrome: a clinical review. Cancer 11 Suppl 1:S1-10, 2005. PMID: 15835720.
148. Poonwalla T, Jones D, Hagemeister FB, Duvic H. Acral necrotizing mycosis fungoides. Clin Lymph Myel 6:146-48, 2005.
149. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle cell lymphoma with Rituximab plus hyper-CVAD alternating with Rituximab plus high-dose Methotrexate and Cytarabine. J Clin Oncol 23(28):7013-23, 2005. e-Pub 2005. PMID: 16145068.
150. Romaguera JE, Hagemeister FB. Lymphoma of the colon. Curr Opin Gastroenterol 21(1):80-84, 2005. PMID: 15687889.
151. Oky Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin's lymphoma. Cancer 104:781-87, 2005.
152. Hagemeister FB. Stem-cell transplant for Hodgkin's lymphoma: Does choice of therapy prior to high-dose treatment matter?. Nat Clin Pract Oncol 2(7):344-45, 2005. PMID: 16075792.
153. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 2004. e-Pub 2004. PMID: 15353540.
154. Hagemeister F. Does high-dose therapy cure more patients with large cell lymphoma than standard CHOP? . Am J Onc Rev 3:68-72, 2004.
155. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10(5):1513-8, 2003. PMID: 12883733.
156. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98:310-4, 2003. PMID: 12872350.
157. Hagemeister FB. Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy. Clin Adv Hematol Oncol 1(2):120-5, 2003. PMID: 16224391.
158. Hagemeister F. Should we continue trials of BMT as initial therapy for aggressive lymphomas at high risk of relapse? . Am J Onc Rev 8:416-417, 2003.
159. Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol 49 Suppl 1:S13-20, 2002. e-Pub 2002. PMID: 12042984.
160. Hagemeister, Fredrick. Treatment Options for Aggressive Lymphomas. Lymph Biol & Res 7:8, 2002.
161. Hagemeister FB. Review of a randomized controlled trial of Yttruim-90-labeled Ibritumomab Tiuxetan radioimmunotherapy versus Rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Am J Oncol Rev 1:222-24, 2002.
162. Hagemeister FB. Rituximab plus hyper-CVAD for mantle cell lymphoma: Updated results. Biol Ther of Lymph 5:3-6, 2002.
163. Hagemeister FB, Donato M. Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience. Eur J Haematol Suppl 64:8-13, 2001. PMID: 11486405.
164. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27(6 Suppl 12):37-41, 2000. PMID: 11225999.
165. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11(1):69-72, 2000. PMID: 10690390.
166. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26(5 Suppl 14):79-87, 1999. PMID: 10561022.
167. Hagemeister FB. The role of ifosfamide in the treatment of lymphomas. Leuk Lymphoma 34(5-6):433-41, 1999. PMID: 10492066.
168. Hagemeister FB. Controversies in the management of early stage Hodgkin’s disease. Can Res Ther Control 7:259-265, 1999.
169. Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma 32(1-2):97-106, 1998. PMID: 10037005.
170. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14(4):1262-8, 1996. PMID: 8648382.
171. Suki S, Swan F, Jr, Tucker S, Fritsche HA, Redman JR, Rodriguez MA, McLaughlin P, Romaguera J, Hagemeister FB, Velasquez WS, et al. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma 18(1-2):87-92, 1995. PMID: 8580834.
172. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 17(5-6):427-33, 1995. PMID: 7549833.
173. Rodriguez, Diaz-Pavon J, Cabanillas F, Majlis A, Hagemeister FB. Outcome of Hodgkin’s disease in elderly patients. Hemat Oncol 13:19-27, 1995.
174. Hagemeister FB, Khetan R, Allen P, McLaughlin P, Rodriguez MA, Swan F, Jr, Romaguera JE, Cabanillas F. Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. Ann Oncol 5 Suppl 2:41-6, 1994. PMID: 8204519.
175. Hagemeister FB, Purugganan R, Fuller L, McLaughlin P, Swan F, Jr, Romaguera J, Rodriguez M, Cabanillas F. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol 31(2 Suppl 3):36-43, 1994. PMID: 8073308.
176. Hagemeister FB, Purugganan R, Podoloff DA, Hess M, Rodriguez MA, McLaughlin P, Swan F, Jr, Romaguera JE, Cabanillas F. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol 5 Suppl 2:59-63, 1994. PMID: 8204521.
177. McLaughlin P, Hagemeister FB, Swan F, Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12(3):575-9, 1994. PMID: 8120556.
178. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 5 Suppl 2:73-7, 1994. PMID: 7515650.
179. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Swan F, Moore DF, Jr, Sarris AH, Younes A, Hill D, Cabanillas F. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Invest New Drugs 12(3):217-22, 1994. PMID: 7896540.
180. Hagemeister FB. Are alkylating agents a necessary component in the therapy of Hodgkin's disease. Leuk Lymphoma 10 Suppl:91-7, 1993. PMID: 7683230.
181. Hagemeister FB. Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology. Leuk Lymphoma 10 Suppl:21-7, 1993. PMID: 7683228.
182. Hagemeister FB, Fuller LM, Velasquez WS, McLaughlin P, Redman JR, Swan F, Rodriguez MA, North L, Dixon D, Silvermintz K, et al. Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's disease. Ann Oncol 2(1):25-31, 1991. PMID: 2009233.
183. Hagemeister FB, Cabanillas F, Velasquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodriguez MA, Swan F, Jr, et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol 17(6 Suppl 10):34-8; discussion 38-40, 1990. PMID: 2259922.
184. Lopez TM, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Redman JR, Rodriguez MA, Tucker SL, Silvermintz K, Johnson J, et al. Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol 8(4):615-22, 1990. PMID: 2313330.
185. Hagemeister FB, Fesus SM, Lamki LM, Haynie TP. Role of the gallium scan in Hodgkin's disease. Cancer 65(5):1090-6, 1990. PMID: 2302660.
186. Fesus SM, Hagemeister FB, Manning J. Hodgkin disease in a patient with common variable immunodeficiency. Am J Hematol 32(2):138-42, 1989. PMID: 2757010.
187. Fuller LM, Hagemeister FB. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease. Recent Results Cancer Res 117:197-204, 1989. PMID: 2602645.
188. Henkelmann GC, Hagemeister FB, Fuller LM. Two cycles of MOPP and radiotherapy for stage III1A and stage III1B Hodgkin's disease. J Clin Oncol 6(8):1293-302, 1988. PMID: 3411342.
189. Hagemeister FB. Prognostic factors in decision-making in the clinical management of Hodgkin's disease. Hematol Oncol 6(3):257-69, 1988. PMID: 3042583.
190. Fuller LM, Hagemeister FB, North LB, McLaughlin P, Velasquez WS, Cabanillas F. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results. Int J Radiat Oncol Biol Phys 14(4):683-92, 1988. PMID: 3280532.
191. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5(4):556-61, 1987. PMID: 3559649.
192. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5(3):407-12, 1987. PMID: 3819806.
193. Pillai GN, Hagemeister FB, Velasquez WS, Sullivan JA, Johnston DA, Butler JJ, Shullenberger CC. Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer 55(4):691-7, 1985. PMID: 2578302.
194. Fuller LM, Hagemeister FB. Diagnosis and management of Hodgkin's disease in the adult. Cancer 51(12 Suppl):2469-76, 1983. PMID: 6687831.
195. Hagemeister FB:. New approaches to management of stage IV Hodgkin’s disease. Cancer Bulletin 35:230-232, 1983.
196. Hagemeister FB, Fuller LM, Sullivan JA, Johnston D, North L, Butler JJ, Velasquez WS, Shullenberger CC. Treatment of patients with stages I and II nonmediastinal Hodgkin's disease. Cancer 50(11):2307-13, 1982. PMID: 6754064.
197. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60(3):693-7, 1982. PMID: 7104493.
198. Hagemeister FB, Fuller LM, Velasquez WS, Sullivan JA, North L, Butler JJ, Johnston DA, Shullenberger CC. Stage I and II Hodgkin's disease: Involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer Treat Rep 66(4):789-98, 1982. PMID: 7074649.
199. Hagemeister FB, Fuller LM, Sullivan JA, North L, Velasquez W, Conrad FG, McLaughlin P, Butler JJ, Shullenberger CC. Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy. Radiology 141(3):783-9, 1981. PMID: 6895415.
200. Rodriguez A, Fayad L, Dang N, Forman A, Goy A, Hagemeister F, McLaughlin P, Medeiros J, Nakamura H, Pro B, Romaguera J, Samaniego F, Samuels B, Sarris A, Younes A, Lu B, Deitcher S, and Cabanillas F. Phase 2 Study of Vincristine Sulfate Liposomal Injection (Maqibo) in Substitution of Conventional Vincristine in CHOP Rituximab for Patients with Untreated Aggressive Non-Hodgkin's Lymphoma.
201. Manoukian G, Hagemeister F, McLaughline P, Fayad L, Samaniego F, Goy A, Romaguera J, Pro B, Hess M, Cabanillas F, Khouri I, Rodriguez A. Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (RFND) for Patients with Relapsed Indolent Lymphoma. Journal of Clinical Oncology.

Invited Articles

1. Hagemeister FB. Maintenance and Consolidation Strategies in Non-Hodgkin's Lymphoma: A Review of the Data. Curr Oncol Rep 12(6):395-401, 2010. e-Pub 2010. PMID: 20820960.
2. Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 9(11):1445-51, 2009. PMID: 19817678.

Editorials

1. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. PMID: 24332512.

Abstracts

1. Nieto Y, Bassett R, Anderlini P, Hosing CM, Alousi AM, Popat UR, Andersson BS, Valdez BC, Shpall EJ, Ahmed S, Qazilbash M, Guillermo M, Oki Y, Fanale M, Hagemeister F, Dabaja BS, Pinnix CC, Milgrom SA, Tewari P, Champlin RE and Jones R. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. Blood 126(23):1980, 2015.
2. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Yago Nieto Y, Davis RE and Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL 126(23):3984, 2015.
3. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Yago Nieto Y, Davis RE and Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood 126(23):2738, 2015.
4. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu S, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE and Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 126(23):1502, 2015.
5. Fowler N, Pinto RM, Cheah CY, Neelapu S, Turturro F, Hagemeister FB, Romaguera JE, Fanale MA, Fayad LE, Forbes S, Khan J, Feng L, Samaniego F and Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood 126(23):1502, 2015.
6. Fanale, MA, Wang Z, Ma W, Oki Y, Hagemeister, F, Fayad, LE, Fowler, N, Romaguera JE, Shah N, Chuang HH, Lei F, Horowitz SB, Chihara D, Wesson E, Hutto T, Ruben C, Samaniego F, Muzzafar T, Piekarz R, Davis RE. Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. Blood 126(23):2705, 2015.
7. Ahmed MA, Oki Y, Noorani M, Nastoupil L, Fayad LE, Hagemeister FB, Rosriguez A, Davis RE and Westin J. The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies. Blood 126(23):3965, 2015.
8. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu JS, Hagemeister FB, Fanale MA, Oki Y, Shah J, Thomoas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ and Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood 123(23):3969, 2015.
9. Nieto Y, Valdez BC, Thall PF, Wei W, Jones R, Hosing CM, Ahmed S, Popat UR, Shpall EJ, Qazilbash M, Gulbis AM, Anderlini P, Shah N, Bashir Q, Alousi AM, Oki Y, Hagemeister FB, Champlin RE and Andersson BS. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. Blood 126(23):1992, 2015.
10. Cheah CY, Chihara D, Sevin A, Horowitz S, Oki Y, Fowler N, Neelapu S, Nastoupil L, Turturro F, Hagemeister F, Westin J, Romaguera J, Fayad L, Samaniego F and Fanale MA. Patients with Classical Hodgkin Lymphoma Failing Brentuximab Vedotin have Brief Responses to Salvage Therapies and Limited Survival. HAA Annual Scientific Meeting 2015, 2015.
11. Phansalkar K, Ahmed MA, Fowler N, Ma L, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale MA, Wang M, Oki Y, Tuturro F, Westin JR, Nastoupil LJ, Kwak LW, Davis RE and Neelapu S. R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood 124:3048, 2014.
12. Feng L, Oki Y, Qazilbash M, Muzzafar T, Weber DM, Fowler N, Popat UR, Thomas SK, Fanale MA, Nieto Y, Shah N, Bashir Q, Hagemeister FB, Orlowski R, Shah JJ. Plasmablastic Lymphoma: 28 Patient Single Institution Experience. Blood (ASH Annual Meeting Abstracts) 122(21):4310, 2013.
13. Thall PF, Valdez BC, Hosing CM, Ahmed S, Jones RB, Shah N, Anderlini P, Qazilbash MH, Popat UR, Bashir Q, Shpall EJ, Alousi A, Kebriaei P, Fox P, Bassett R, Chancoco C, Oki Y, Fanale MQ, Fowler N, Hagemeister FB, Romaguera JE, Champlin RE, Andersson BS. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. Blood (ASH Annual Meeting Abstracts) 122(21):2095, 2013.
14. Fanale MA, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Younes A. A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL). Blood (ASH Annual Meeting Abstracts) 122(21):252, 2013.
15. Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez MA, Oki Y, Westin JR, Turturro F, Overman MJ, Neelapu SS, Fowler N, Fayad LE. Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). Blood (ASH Annual Meeting Abstracts) 122(21):3028, 2013.
16. Noorani M, Davis RE, Neelapu SS, Rodriguez AM, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood (ASH Annual Meeting Abstracts) 122(21):1776, 2013.
17. Hagemeister FB, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris AH, and Cabanillas F. Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas. Blood (ASH Annual Meeting Abstracts) 122(21):3033, 2013.
18. Romaguera JE, Fanale MA, Samaniego F, Fayad LE, Hagemeister FB, McLaughlin P, Rodriguez MA, Weaver P, Hartig K, Badillo M, Kwak LW, Younes A, Pro B, and Wang M. Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 122(21):5122, 2013.
19. Fanale M, Lai C, Rimes S, Ramirez M, Hagemeister F, Fowler N, Younes A, Fayad L, Rodriguez MA, Turturro F, Samaniego F, Romaguera J, Levin V, Horowitz S, Woolery J and Milbourne A. Positive maternal-fetal outcomes with treatment of lymphoma during pregnancy: UT MD Anderson Cancer Center Prospective. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
20. Oki Y, Westin J, Fowler N, Neelapu S, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M, Younes A, Rodriguez MA, Orlowski R, Wang M, Ouzanian S, Smaniego F, and Fayad L. R-HCVAD alternating with R-methotrexate cytarabine in younger patients (pts) with IH and high-risk age adjusted-ipi- DLBCL. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
21. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu S. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
22. Oki Y, Chuang H, Chasen B, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez A, Neelapu S, Samaniego F, Kwak L, and Younes A. The prognostic value of interim PET scan in patients with classical Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
23. Fowler N, Neelapu S, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M, Fayad L, Orlowski R, Wang M, Turturro F, Oki Y, Lacerte L, and Samaniego F. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a phase II study. Blood (ASH Annual Meeting Abstracts) 120(21), 2012.
24. Fowler N, Neelapu S, Fanale M, Rodriguez M, Pro B, Hagemeister F, Younes A, Shah J, Kwak L, Rodriguez D, McLaughlin P. Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 2011.
25. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera J, Fanale M, Fayad L, Fowler N, Huen A, Hagemeister F, Rodriguez A, Neelapu S, Samaniego F, Younes A, Kwak L. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multiday Chemotherapy Regimen of Cyclophosphamide, Doxorubicon, vincristine, prednisone, +/- Rituxan (R/CHOP): Randomized, Double-blind, Placebo-Controlled Study. Blood (ASH Annual Abstracts) 118(21), 2011.
26. Younes A, Copeland A, Fanale M, Fayad L, Romaguera J, Kwak L, Neelapu S, Hagemeister F, Pro B, Faria S, Ji Y, Berry D, Buglio D, and Medeiros J. Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 2011.
27. Thomas D, O'Brien S, Cortes J, Faderl S, Wierda W, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Burger J, Garris R, Romaguera J, Hagemeister F, and Kantarjian H. Long-term outocme for De Novo or minimaly treated Burkitt-type lymphoma/leukemia (BL/B-ALL) after therapy with hyper-CVAD and rituximab. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010.
28. Hamlin P, Rodriguez M, Noy A, Portlock C, Straus D, McLaughlin P, Pro B, Fayad L, Hagemeister F, Wegner B, Dumitrescu O, Tasker N, Moskowitz C, and Zelenetz A. Final results of a Phase II study of sequential R-CHOP and yttrium-90 ibritumumab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL). American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010.
29. Fanale M, Lai C, McLaughlin P, Romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu S, Shah J, Kwak L, Dong W, Reed V, Dabaja B, Popat U and Younes A. Outocmes of nodular lymphomcyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010.
30. Batty N, Ghonimi E, Feng L, Younes A, Rodriguez MA, Wager E, Martinez F, Wang M, McLaughlin P, Fowler N, and Hagemeister F. Blood transfusion and erythropoiesis stimulating agents (ESAs) use in patients with diffuse large B-cell lymphoma (DLBCL). American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010.
31. Younes A, Copeland A, Fanale M, Hagemeister F, Fayad L, Pro B, Faria S, Ji Y, Medeiros J, Berry D, and Buglio D. Phase I/II study of the novel combinationof panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010.
32. Vadhan-Raj S, hagemeister F, Fayad L, Zhou X, O'Roark S, Ames K, Rodriguez MA, Fanale M, Pro B, Johnson M, McLaughlin P, Bueso-Ramos C, Younes A, Kwak L, and Romaguera J. Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): Results of a phase I/II study. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010.
33. Okoroji G, Silva L, Saliba R, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriael P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, and Khouri I. Outcome in follicular lymphoma (FL) patients (pts) relapsing after autologous stem cell transplantation (ASCT): Allografting vs conventional therapy. American Society of Hematology 52nd Annual Meeting Abstracts 116(21), 2010.
34. Pozazides JV, Perini G, Hess M, Romaguera JE, Hagemeister FB, McLaughlin P, Fayad L, Khouri IF, Hosing C, Pro B. Prognosis and treatment of patients with peripheral t-cell lymphoma: The MD Anderson Cancer Center experience. ASCO 2010 Annual Meeting Abstracts, 2010.
35. Fowler N, McLaughlin P, Hagemeister FB, Kwak LW, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. ASCO Annual Meeting Abstracts, 2010.
36. Pro B, Perini GF, Feng l, Romaguera JE, Rodriguez MA, McLaughlin P, Hagemeister FB, Fayad L, Kadia T. Clinical features and treatment outcomes of angioimmunoblastic t-cell lymphoma. 2010 ASCO Meeting Abstracts, 2010.
37. Batty N, Hagemeister FB, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study. 2010 ASCO Annual Meeting Abstracts, 2010.
38. Perini GF, Romaguera JE, Rodriguez MA, Pro B, Younes A, Fowler N, Hagemeister FB, Samaniego F, Kwak LW, Fayad L. Diffuese large b-cell lymphoma (DLBCL) with bone marrow (BM) involvement, clinical presentation, central nervous system (CNS) relapses, and outcome of 121 patients treated at MD Anderson Cancer Center. 2010 ASCO Meeting Abstracts, 2010.
39. Manoukian GE, Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). 2010 ASCO Annual Meeting Abstracts, 2010.
40. Westin JR, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Kwak LW, Hagemeister FB. The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy. 2010 ASCO Annual Meeting Abstracts, 2010.
41. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah N, Samaniego F, Younes A, Kwak L, Romaguera J. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. Journal of the American Society of Hematology 114(22):48, 2009.
42. Younes A, Gordon L, Kim S, Romaguera J, Copeland A, de Castro Farial S, Kwak L, Fayad L, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL). Journal of the American Society of Hematology 114(22):243, 2009.
43. Copeland A, Cao Y, Fanale M, Fayad L, McLaughlin P, Pro B, Hagemeister F, Romaguera J, Samaniego F, Rodriguez A, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Results of Long Follow up and Comparison to Institutional Historical Data. Journal of the American Society of Hematology 114(22):670, 2009.
44. Fowler N, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu S, Fayad L, Pro B, Sergent C, White S, Samaniego F. A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 114, 2009.
45. Wang L, Fayad L, Hagemeister F, Neelapu S, Samaniego F, McLaughlin P, Samuels B, Yi Q, Pro B, Fanale M, Shah J, Younes A, Bell N, Knight R, Zeldis J, Cabanillas F, Kwak L, Romaguera J. A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 114, 2009.
46. Westin J, Thompson M, Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone loss in lymphoma patients receiving frontline therapy: Urine Ntx and bone specific alkaline phosphatase provide early evidence of zoledronic acid response. Blood (ASH Annual Meeting Abstracts) 114, 2009.
47. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister F. Differential JAK-STAT Pathway Activation in primary mediastinal large b-cell lymphoma: Two subgroups with differential cytokine activation patterns and predicted responses to kinase inhibitors. Blood (ASH Annual Meeting Abstracts) 114, 2009.
48. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera J. Randomized clinical trial of rasburicase administered as a standard fixed five days dosing vs a single dose followed by as needed dosing in adult patients with hematologic malignancies at risk for developing tumor lysis syndrome. Blood (ASH Annual Meeting Abstracts) 114, 2009.
49. Younes A, Gordon L, Kim S, Romaguera J, Copeland A, de Castro F, Kwak L, Fayad L, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory b-cell non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 114, 2009.

Book Chapters

1. Chihara D, Hagemeister FB, Medeiros LJ, Fanale M. Hodgkin Lymphoma. In: The MD Anderson Manual of Medical Oncology. 3rd. Cenveo: New York, USA, 201-227, 2016.
2. Rios A, Hagemeister FB. AIDS-Related Cancers. In: The MD Anderson Anual of Medical Oncology. 2nd. McGraw-Hill Companies: China, 1141-1171, 2011.
3. Westin J, Hagemeister F, Fanale M. Hodgkin Lymphoma. In: The MD Anderson Manual of Medical Oncology. 2nd. The McGraw-Hill Companies: China, 203-243, 2011.